ACE-031, at a dose of 1mg, is now generating significant interest across European markets. Initial clinical studies in regions such as Germany, France and its neighbors, and the Great Britain have indicated positive results in treating specific neurological ailments. Regulatory agencies across the area are carefully assessing the findings for poten